Study of GS-0151 in Participants With Rheumatoid Arthritis
Phase 1
75
about 1.9 years
18–75
15 sites in AL, CA, FL +6
What this study is about
Researchers are testing a treatment called GS-0151 to see if it's safe and how well the body absorbs, changes, distributes, and eliminates it. The trial will last for 686 days and involve approximately 75 participants with rheumatoid arthritis.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take GS-0151
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Cohort 1, 2 and 3: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs), Cohorts 1, 2 and 3: Percentage of Participants Experiencing Serous Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Discontinuation, Cohorts 1, 2 and 3: Serum Cmax, Following the Last Dose of GS-0151, Cohorts 1, 2 and 3: Serum Tmax Following the Last Dose of GS-0151
Secondary: Cohort 3: Change From Baseline in Disease Activity Score for 28 Joint Count Using C-Reactive Protein (DAS28-CRP) at Week 12 in Participants With Moderately to Severely Active RA
Immune